Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only the general boxed-warning statements about NSAID cardiovascular thrombotic risk and serious GI bleeding/ulceration/perforation are supported by the provided label excerpts. Most other claims (statin/muscle effects, specific interaction guidance, kidney/BP/heart failure/pregnancy/monitoring and specific symptom lists) are not supported or contradicted by the excerpts supplied, so overall alignment is limited.
Category Scores
Accurate Statements
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID).
Not explicitly supported by the excerpts provided; however the excerpts state 'NSAIDs, including meloxicam' (Boxed Warning and Section 5.2), implying meloxicam is an NSAID.
Meloxicam can increase the risk of stomach irritation, ulcers, or bleeding.
Supported by Boxed Warning and Section 5.2: 'serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation' and includes ulceration/bleeding (serious GI events).
Avoid taking other NSAIDs at the same time as meloxicam.
Not supported or contradicted by the provided excerpts (no interaction/avoidance statement in supplied text).
Using the lowest effective meloxicam dose for the shortest time is a common safety step if the combination is approved.
Supported generally for NSAID use: Section 5.1 states 'use the lowest effective dose for the shortest duration possible.' The excerpt does not address 'combination is approved' wording.
Unsupported Statements
There is not a common direct drug–drug interaction that automatically prevents using meloxicam and statins together.
No statin-specific interaction statement appears in the provided label excerpts.
Meloxicam can stress the kidneys and increase blood pressure.
No kidney or blood pressure effects are described in the provided excerpts.
Statins can rarely cause muscle injury (myopathy/rhabdomyolysis).
No statin-specific adverse effect statement appears in the provided label excerpts.
NSAIDs do not typically cause the same muscle problem as statins.
No NSAID vs statin muscle effect comparison appears in the provided label excerpts.
You should check with a clinician or pharmacist before using meloxicam if there is a history of stomach ulcers or GI bleeding.
The label excerpts identify 'patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk' but do not provide this specific 'check with a clinician...' instruction.
You should check with a clinician or pharmacist before using meloxicam if there is chronic kidney disease, reduced kidney function, or higher risk of dehydration.
No kidney/dehydration guidance appears in the provided excerpts.
You should check with a clinician or pharmacist before using meloxicam if there is uncontrolled high blood pressure or heart failure.
No blood pressure/heart failure guidance appears in the provided excerpts.
You should check with a clinician or pharmacist before using meloxicam if you take blood thinners (such as warfarin), antiplatelets (such as clopidogrel), or other NSAIDs (such as ibuprofen or naproxen).
No drug class interaction or 'check with clinician' instruction for these agents appears in the provided excerpts.
You should check with a clinician or pharmacist before using meloxicam if you are pregnant or planning pregnancy.
No pregnancy-related information appears in the provided excerpts.
New, unexplained muscle pain or weakness after starting or increasing a statin dose should be taken seriously and discussed with a clinician.
No statin symptom guidance appears in the provided excerpts.
Staying hydrated is recommended, especially if you also take diuretics or blood pressure medicines.
No hydration/diuretic/BP medicine guidance appears in the provided excerpts.
If you take meloxicam while on a statin, you should tell your clinician if you get stomach pain, black/tarry stools, vomiting blood, reduced urination, sudden swelling, or severe muscle symptoms.
While black/tarry stools/vomiting blood relate to GI bleeding, the provided excerpts do not list these specific action-symptom instructions and the rest (reduced urination/sudden swelling/severe muscle symptoms) are not supported by the excerpts.
Contact a clinician promptly for severe muscle pain or weakness.
No muscle symptom action guidance appears in the provided excerpts.
Contact a clinician promptly if muscle symptoms occur with fever, dark/tea-colored urine, or feeling very unwell.
No fever/dark urine/overall severe muscle syndrome guidance appears in the provided excerpts.
Contradictions
Low
AI Statement
There is not a common direct drug–drug interaction that automatically prevents using meloxicam and statins together.
Label Reference
No contradiction identified; not supported and cannot be confirmed either way from supplied excerpts.
Important Omissions
Boxed warning also includes increased risk of serious cardiovascular thrombotic events (MI and stroke) and states risk may occur early and may increase with duration. The provided claims list does not include these specific cardiovascular boxed-warning details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes some supported GI risk information and the 'lowest effective dose/shortest duration' concept, but it makes multiple unsupported patient-management assertions (kidney/BP/heart failure/pregnancy/statin muscle-effect comparisons and specific monitoring for combined meloxicam+statin use) that cannot be verified against the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Most claims are not supported by the provided prescribing information excerpts, including statin-related muscle effects, specific interaction/monitoring guidance, and kidney/BP/heart failure/pregnancy cautions.
Suggested Improvement
Limit statements to the provided label-supported boxed warning and Sections 5.1 (CV thrombotic risk and lowest effective dose/shortest duration) and 5.2 (serious GI bleeding/ulceration/perforation risk and risk factors), and avoid unsupported statin- and symptom-specific action guidance unless present in the full label text.